The medical community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a more substantial decre